Malignant hyperthermia prevention

Malignant hyperthermia prevention refers to prophylactic intervention in patients known or suspected to be susceptible to malignant hyperthermia—a rare, life-threatening pharmacogenetic disorder of skeletal muscle Susceptible individuals typically harbor autosomal dominant mutations in the ryanodine receptor gene (*RYR1*) or the voltage-gated calcium channel subunit gene (*CACNA1S*), which impair regulation of myoplasmic calcium release When these individuals are exposed to triggering agents, pr...

Malignant hyperthermia prevention refers to prophylactic intervention in patients known or suspected to be susceptible to malignant hyperthermia—a rare, life-threatening pharmacogenetic disorder of skeletal muscle When these individuals are exposed to triggering agents, predominantly volatile halogenated inhalational anesthetics or depolarizing muscle relaxants such as succinylcholine, dysregulated calcium influx causes sustained muscle contraction and a profound hypermetabolic crisis Prophylaxi...

Susceptible individuals typically harbor autosomal dominant mutations in the ryanodine receptor gene (*RYR1*) or the voltage-gated calcium channel subunit gene (*CACNA1S*), which impair regulation of myoplasmic calcium release Prophylaxis aims to prevent the onset of this hypermetabolic cascade and its associated features, including pronounced hypercarbia, metabolic acidosis, generalized muscle rigidity, hyperthermia, rhabdomyolysis, and cardiovascular collapse